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Abstract
Purpose Since the introduction of positron emission tomog-
raphy (PET) imaging with 68Ga-PSMA-HBED-CC (= 68Ga-
DKFZ-PSMA-11), this method has been regarded as a signif-
icant step forward in the diagnosis of recurrent prostate cancer
(PCa). However, published data exist for small patient cohorts
only. The aim of this evaluation was to analyse the diagnostic
value of 68Ga-PSMA-ligand PET/CT in a large cohort and the
influence of several possibly interacting variables.
Methods We performed a retrospective analysis in 319 pa-
tients who underwent 68Ga-PSMA-ligand PET/CT from 2011
to 2014. Potential influences of several factors such as
prostate-specific antigen (PSA) level and doubling time
(DT), Gleason score (GSC), androgen deprivation therapy
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(ADT), age and amount of injected tracer were evaluated.
Histological verification was performed in 42 patients after
the 68Ga-PSMA-ligand PET/CT. Tracer uptake was measured
in 901 representative tumour lesions.
Results In 82.8 % of the patients at least one lesion indicative
of PCa was detected. Tumor-detection was positively associ-
ated with PSA level and ADT. GSC and PSA-DT were not
associated with tumor-detection. The average maximum stan-
dardized uptake value (SUVmax) of tumour lesions was 13.3±
14.6 (0.7–122.5). Amongst lesions investigated by histology,
30 were false-negative in 4 different patients, and all other
lesions (n=416) were true-positive or true-negative. A lesion-
based analysis of sensitivity, specificity, negative predictive
value (NPV) and positive predictive value (PPV) revealed
values of 76.6 %, 100 %, 91.4 % and 100 %. A patient-
based analysis revealed a sensitivity of 88.1 %. Of 116 pa-
tients available for follow-up, 50 received local therapy after
68Ga-PSMA-ligand PET/CT.
Conclusion 68Ga-PSMA-ligand PET/CT can detect recurrent
PCa in a high number of patients. In addition, the radiotracer is
highly specific for PCa. Tumour detection is positively asso-
ciated with PSA and ADT. 68Ga-PSMA-ligand PET/CT can
help delay systemic therapy of PCa.
Keywords Prostate cancer . PET/CT . Positron emission
tomography . PSMA . FMCH . FECH
Introduction
Prostate cancer (PCa) is the most frequent tumour entity in
men worldwide and an increasing incidence has been noted in
recent years [1]. An important problem in clinical manage-
ment is the development of tumour recurrence after prostatec-
tomy, radiotherapy or other local treatment modalities. In most
cases, recurrence after initial therapy is diagnosed either by
two consecutive prostate-specific antigen (PSA) values
of ≥0.2 μg/l after prostatectomy or external beam radi-
ation therapy [2].
One of the key issues is early detection of recurrent disease.
If the tumour is accessible for surgery or external radiation
therapy, patients may be cured or systemic therapy and the
resultant side effects can be delayed. However, the prerequi-
site of these approaches is an accurate diagnostic modality
with high sensitivity and specificity. To date, this is a major
challenge for all conventional imaging methods [3].
Although choline-based positron emission tomography
(PET)/CT is widely used for this purpose, there have been
numerous studies reporting a low sensitivity and specificity,
especially at low PSA levels and high Gleason scores (GSC)
[4–8]. Therefore, the development of new and improved im-
aging methods was required. In this context, the prostate-
specific membrane antigen (PSMA) has recently received
increased attention [9–13]. This cell surface protein is signif-
icantly overexpressed in PCa cells compared to other PSMA-
expressing tissues such as kidney, proximal small intestine or
salivary glands [14, 15]. It therefore provides a promising
target for PCa-specific imaging and therapy [10, 11, 16–23].
Amongst the methods available to image PSMA-expressing
tumours, Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]
(68Ga-DKFZ-PSMA-11) as a 68Ga-labelled PSMA-targeted
radioligand developed by our group became one of the most
successful with respect to clinical application showing a
rapid spread across many countries. However, to date data
exist only for a limited number of patients, and the influ-
ence of several parameters used for follow-up and assess-
ment of prognosis has not been addressed. The aim of this
evaluation was to retrospectively analyse a greater number
of patients investigated with this imaging modality as well
as possibly interacting variables such as PSA level, GSC,
androgen deprivation therapy (ADT), age and amount of
injected radiotracer.
Materials and methods
For this evaluation we performed a retrospective analysis of
319 patients (Table 1 and Supplementary Table 1) who
underwent PET/CT 1 h post-injection (p.i.) of 68Ga-PSMA-
HBED-CC (= 68Ga-DKFZ-PSMA-11) between May 2011
and January 2014 at our department. All patients signed a
written informed consent form for the purpose of anonymized
evaluation and publication of their data. All reported investi-
gations were conducted in accordance with the Helsinki Dec-
laration and with our national regulations. This evaluation was
approved by the Ethics Committee of the University of Hei-
delberg (permit S-321/2012). One hundred and two patients in
the present evaluation had been partially analysed in previous
studies [18–21, 24–26]. The authors are convinced that these
patients had to be included in the present evaluation instead of
being excluded. Their inclusion improves the data quality and
significantly strengthens statistical analysis and conclusions.
Patients who did not sign the written informed consent (n=19)
and those who were investigated outside a time frame of 45–
75 min p.i. (n=18) were excluded from this evaluation.
In most patients (n=292) progressive disease was
suspected following prior conventional treatment of PCa
(e.g. radiation therapy and/or surgery). In 27 cases, PET/CT
was conducted before initiation of local therapy to exclude
metastases after PCa was confirmed by biopsy and in 38 cases
(also progressive disease) to evaluate possible therapy with
radiolabelled PSMA ligands [21]. Patients with very low PSA
values were referred to PSMA imaging after progressive
disease was suspected in alternative imaging modalities
such as computed tomography (CT) or magnetic reso-
nance imaging (MRI).
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To increase the validity of the statistical analysis, only the
initial PET/CTof each patient was included in this evaluation,
regardless of whether theywere referred for more scans during
follow-up. The analysed patients were therefore not strictly
consecutive.
Amongst all lesions visually considered typical for PCa
(for more details, see the “Imaging” section), we selected 901
representative lesions for radiotracer uptake analysis mea-
sured in maximum standardized uptake value (SUVmax) as
this is common in routine clinical practice. Any visible PCa
lesion of a patient was counted and analysed unless they had
more than ten lesions. In such a case a maximum of ten lesions
were analysed after random selection. This kind of selection
avoids an overestimation of SUV values as otherwise dominant
lesions would be preferentially selected. In addition, since 68Ga-
PSMA-ligand PET/CT was introduced, we learned that any
uptake of 68Ga-PSMA-HBED-CC in lesions above local back-
ground is highly specific for PCa andmust therefore be regarded
as PCa unless otherwise proven (see also histological results).
Therefore, a quantitative cut-off for PCa lesions does not exist.
Forty-two patients with pathological radiotracer uptake in
68Ga-PSMA-ligand PET/CTwere further investigated by biop-
sy or surgery at our hospital. Biopsies and operative findings
not conducted at our hospital were not included in this evalu-
ation due to insufficient access to the pathological reports. The
histology results were compared with the findings of the
68Ga-PSMA-ligand PET/CT. An experienced physician from
the Department of Urology was involved in this comparison. A
lesion-based analysis of sensitivity, specificity, negative predic-
tive value (NPV) and positive predictive value (PPV) was
performed. With regard to a patient-based analysis, calculating
specificity, NPV and PPV is not possible as we assume that
virtually all patients referred to our hospital had recurrent
disease or persistent primary tumour and that our cohort there-
fore did not include true-negative cases. Under this assumption,
a patient-based sensitivity of the 68Ga-PSMA-ligand PET/CT
was calculated, however, with limited validity as no standard-
ization existed for operative approaches and histology. Thus, no
true gold standard for patient-wise positivity/negativity existed.
In particular, a negative local histology did not mean that no
tumour existed in patients. Follow-up could be conducted in
116 patients up to the time this manuscript was submitted.
We also investigated whether the uptake of the radiotracer in
salivary glands can be reduced by a sour excretion stimulus. For
this reason, ten patients orally received 10 ml of a vitamin C
solution every 30 min (overall three times) after the first scan
(1 h p.i.) and were then investigated by a second scan 3 h p.i.
The uptakes (SUVmean and SUVmax) of the salivary glands were
then measured at 1 and 3 h p.i. and compared to our previous
evaluation [19]. The vitamin C solution was prepared by adding
3 g of vitamin C powder to 10 ml of water. In addition, the
patients were asked to drink 1 l of water between both scans.
Imaging
68Ga3+ was obtained from a 68Ge/68Ga radionuclide generator
and used for radiolabelling of PSMA-HBED-CC as previous-
ly described [10, 11]. The final product was formulated in
isotonic phosphate-buffered saline (PBS) and sterile filtered.
The radiolabelling and purification of the PSMA ligand was
performed with an automated radiosynthesizer. Typically, the
radiochemical yield is >98 % as determined by
radiosynthesizer validation. The 68Ga-PSMA-HBED-CC so-
lution was applied to the respective patient via an intravenous
bolus injection (mean of 172.4 MBq ±70.9, range 40–
400 MBq, median 161 MBq). The targeted activity of 68Ga-
Table 1 Characteristics of the patients investigated in this study (for more details, see Supplementary Table 1)
Age (y) [n=319] Tracer (MBq) [n=319] GSC [n=284] PSA at PET [n=311]
Mean 67.6 168 7.5 161.0
SD 7.1 71.4 1.1 2347.6
Range 46-86 40–400 5–10 0.01–41395
Median 68 154 7 4.59




PSA Doubling-Time [n/a: n=127]
0–1 month (n=30) 1–3 months (n=52) 3–6 months (n=36) 6–12 months (n=34) >1 year (n=37)
Initial Pathological Stage (TNM) [Incomplete TNM: n=44. n/a: n=91]
pT1 pN0 (n=4) pT2 pN0 (n=61) pT3a pN0 (n=30) pT3b/pT4 + pN0 (n=29) any pT and pN+ (n=60)
SD standard deviation
a Radiation therapy of the prostate gland or of the prostate fossa after prostatectomy
Eur J Nucl Med Mol Imaging (2015) 42:197–209 199
PSMA-HBED-CC was 2 MBq/kg body weight. Variation of
injected radiotracer activity was caused by the short physical
half-life of 68Ga (68 min) and variable elution efficiencies
resulting during the lifetime of the 68Ge/68Ga generator. How-
ever, in our experience with 68Ga-PSMA-ligand PET/CT dur-
ing the last 3 years, all injected activities were sufficient in
detecting PCa. All injections contained 2 nmol PSMA ligand
resulting in a median specific radioactivity of 80.5 GBq/μmol.
A non-contrast-enhanced CT scan was performed 1 h post
tracer injection using the following parameters: slice thickness
of 5 mm, increment of 1.5 mm, soft tissue reconstruction
kernel, 130 keVand 80 mAs. Immediately after CT scanning,
a whole-body PETwas acquired in 3-D (matrix 168×168). For
each bed position (16.2 cm, overlapping scale 4.2 cm) a 4-min
acquisition time with a 15.5-cm field of view (FOV) was used.
The emission data were corrected for randoms, scatter and
decay. Reconstruction was conducted with an ordered subset
expectation maximization (OSEM) algorithm with 2
iterations/8 subsets and Gauss-filtered to a transaxial resolu-
tion of 5 mm at full-width at half-maximum (FWHM). Atten-
uation correction was performed using the low-dose non-
enhanced CT data. PET and CT were performed using the
same protocol for every patient on a Biograph 6 PET/CT
scanner (Siemens, Erlangen, Germany). Image analysis was
performed using an appropriate workstation and software
(Syngo TrueD, Siemens, Erlangen, Germany).
Two board certified specialists in nuclear medicine with 10
and 9 years of clinical experience (first and third author) read
all data sets independently and resolved any disagreements by
consensus. Lesions that were visually considered as sugges-
tive for PCa were counted and analysed with respect to their
localization (local relapses, lymph node, bone and soft tissue
metastases) and their SUVmax as it is common practice in the
daily routine. SUVmax was chosen due to its higher reproduc-
ibility between different investigators when compared to
SUVmean. The latter is always dependent on the volume of
interest (VOI) drawn by the investigator, whereas SUVmax
behaves independently [19]. However, with regard to the
evaluation of tracer uptake in salivary glands prior to and after
the excretion stimulus, SUVmean was also measured to ensure
a detailed comparison to the results of our previous evaluation
[19]. For calculation of the SUV, circular regions of interest
were drawn around areas with focally increased uptake in
transaxial slices and automatically adapted to a 3-D VOI at a
70 % isocontour.
Statistical analysis
For statistical analysis, Excel 2010 (Microsoft, Redmond,
WA, USA), SigmaPlot version 12 software (Systat Software
Inc., Chicago, IL, USA) and R version 3.01 were used. In all
cases a p value of <0.05 was considered statistically signifi-
cant. The following statistical analyses were used:
1. The association between positive (pathological) PET/CT
results and the variables hormonal therapy (at the time of
PET/CT), age, amount of injected tracer, PSA level and
GSC was investigated, both univariately (n=319 for hor-
monal therapy, n=319 for age and injected tracer, n=311
for PSA and n=284 for GSC) and multivariately (n=277)
using logistic regression.
& GSC was included in this analysis in four different
classes: GSC 5–6 (as reference, all other GSC classes
were compared to GSC 5–6), GSC 7, GSC 8 and GSC
9–10.
& Injected tracer amount was included as multiples of
100 MBq. The odds ratios therefore refer to changes
of 100 MBq.
& Similar to injected tracer amount, age was included as
multiples of 10 years.
& As PSA levels showed a highly skewed distribution,
they were converted to a natural logarithmic scale (log
PSA).
2. The association between positive (pathological) PET/CT
results and PSA doubling time (DT) was also investigat-
ed, both univariately (n=189) and multivariately (n=171)
using logistic regression. As the inclusion of the PSA DT
to the multivariate analysis of all other variables would
reduce the patient cohort significantly (from 277 to 171),
we decided to analyse this variable separately (Supple-
mentary Table 2). PSADTwas included in this analysis in
five different classes: up to 1 month (n=30, as reference,
all other PSA DTclasses were compared to PSA DTup to
1 month), 1–3 months (n=52), 3–6 months (n=36), 6–
12 months (n=34) and >1 year (n=37).
3. Proportions of positive PET results were calculated for
subgroups defined by PSA levels and GSC. Exact bino-
mial 95 % confidence intervals were determined for these
estimates.
4. A two-sided unpaired two-sample t test was used to
evaluate differences concerning GSC between groups
with and without pathological uptakes.
Results
There were no adverse or clinically detectable pharmacological
effects in any of the patients following injection of the radio-
tracer. In 264 of 319 patients (82.8 %) at least 1 lesion charac-
teristic for PCa was detected in 68Ga-PSMA-ligand PET/CT.
Figures 1 and 2 show lymph node metastases as well as
unifocal and multifocal primary PCa. Figures 3 and 4 demon-
strate the probability of a pathological 68Ga-PSMA-ligand
200 Eur J Nucl Med Mol Imaging (2015) 42:197–209
Fig. 1 68Ga-PSMA-ligand PET/
CT demonstrating two different
patients with small lymph node
metastases and different intensity
of tracer uptake. Both patients had
GSC 7. According to our
experiences and the histological
analysis, even low 68Ga-PSMA-
HBED-CC accumulations in
lesions outside the prostate gland
have to be regarded as PCa-
specific until proven otherwise.
Red arrows point to lymph node
metastases. Colour scales were
automatically produced by the
PET/CT machine. a CT of the
first patient, b CT of the second
patient, c fusion of PETand CTof
the first patient, d fusion of PET
and CT of the second patient
Fig. 2 A patient with multifocal
PCa (a, c) and another patient (b,
d) with unifocal PCa with a rarely
seen inguinal lymph node
metastasis. Red arrows point to
PCa within the prostate gland and
blue arrow points to an inguinal
lymph node metastasis. Both
patients had GSC 7, although the
tumours present with different
contrast. Colour scales were
automatically produced by the
PET/CT machine. a Low-dose
CTof the patient with a multifocal
PCa, c corresponding fusion of
PET and low-dose CT 1 h p.i., b
low-dose CT of the patients with
the unifocal PCa, d corresponding
fusion of PET and low-dose CT
1 h p.i.
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PET/CT depending on PSA level (311 patients) and GSC (284
patients).
Patients with pathological radiotracer uptake (n=264) had
a median PSA of 6.02 ng/ml (range 0.01–41,395 ng/ml), a
median GSC of 7.0 (range 5–10) and were injected with a
mean activity of 165.2 MBq 68Ga-PSMA-HBED-CC (range
40–388 MBq, median 152.5 MBq). Patients without patho-
logical findings (n=55) had a median PSA of 1.14 ng/ml
(range 0.03–15.8 ng/ml), a mean GSC of 7.28 (range 5–9,
median 7.0) and were injected with a mean of 180.0±
82.6 MBq radiotracer (range 66–400 MBq, median
160.0 MBq).
In the univariate analysis no significant difference was
found between PET-positive and PET-negative patients with
regard to the injected amount of 68Ga-PSMA-HBED-CC (lo-
gistic regression p=0.165) and GSC (t test p=0.063). How-
ever, concerning log PSA a significant difference was found
(logistic regression p<0.001).
Considering only the subgroup of the most challenging
patients (those with PSA <0.2 ng/ml, Supplementary Table 3),
no significant difference was found regarding either the
injected amount of 68Ga-PSMA-HBED-CC or the log PSA
values, while GSCwas significantly higher (t test p=0.004) in
the group with pathological 68Ga-PSMA-ligand PET/CT.
In the multivariate analysis, a strong and significant asso-
ciation was detected between a positive PET result and the
following parameters: log PSA level and ADT. No significant
or relevant association was detected between a positive PET
result and the following parameters: GSC 7, GSC 8, GSC 9–
10 (all vs GSC 5–6), age and any of the defined PSA DTs. A
noticeable but nonsignificant positive association was also
detected between a positive 68Ga-PSMA-ligand PET/CT and
lower amounts of injected radioactivity. The univariate anal-
ysis demonstrated no principal shifting with regard to the
effect of the single variables. All uni- and multivariate values
are listed in Supplementary Table 2.
Fig. 3 Probability of a
pathological 68Ga-PSMA-ligand
PET/CTas histogram (above) and
plot of the rates of pathological
PET/CTs with confidence
intervals (below) depending on
PSA levels in 311 patients. Blue
columns include the number of
pathological PET/CTs and their
rate in %
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SUVmax values of 901 representative tumour lesions were
as listed in Table 2. Of the lesions, 13 were defined as local
relapses after prostatectomy, 328 as lymph node metastases,
129 as soft tissuemetastases, 359 as bonemetastases and 72 as
vital tumour lesions within the prostate gland, no matter
whether they were pretreated or not. Included in the cohort
of 72 lesions within the prostate gland are: (1) cases in which
PET/CT was conducted before initiation of local therapy to
exclude metastases after PCa was confirmed by biopsy, (2)
patients who were pretreated by radiation therapy without
surgery (we decided to list these patients in the “72 group”
as it remains unclear if the primary tumours in PET/CT were
relapses or residual vitality in tumours after radiation) and (3)
patients who were pretreated by ADT only.
Forty-two patients with pathological radiotracer uptake in
68Ga-PSMA-ligand PET/CTwere further investigated by biop-
sy or surgery at our hospital. The results are listed in Table 3. In
this analysis, 1 local relapse in 1 patient and 29 lymph nodes in
3 other patients were false-negative. All other tissues/lesions
were true-positive (n=98) or true-negative (n=318). With re-
gard to patients 34 and 37 in Table 3, PET-positive lymph nodes
led to lymph node dissection of the pelvis where additional
small lymph node metastases were found in the same region.
Fig. 4 Probability of a
pathological 68Ga-PSMA-ligand
PET/CTas histogram (above) and
plot of the rates of pathological
PET/CTs with confidence
intervals (below) depending on
GSC in 284 patients. Blue
columns include the number of
pathological PET/CTs and their
rate in %
Table 2 Average SUVmax of all types of PCa lesions
SUVmax (± SD) Min. Max. Median
All Tumor Lesions (n=901) 13.4 (±14.6) 0.7 122.5 8.1
Local Relapse (n=13) 11.3 (±6.6) 2.4 22.8 11.3
LymphNodeMetastases (n=328) 14.2 (±17.1) 1.0 122.5 7.0
Soft Tissue Metastases (n=129) 8.4 (±8.0) 0.7 47.5 6.0
Bone Metastases (n=359) 14.3 (±14.0) 1.6 115.4 9.8
Primary PCa (n=72) 11.0 (±9.0) 3 40 7.1
SD standard deviation
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Table 3 Summary of histological investigations of 42 patients: 1 local relapse in 1 patient and 29 lymph node metastases in 3 other patients were false-
negative. All other lesions (n=416) were true-positive or true-negative
All Lesions: False-Negative False-Positive True-Negative True-Positive
Prostate Cancer 0 0 2 15
Soft Tissue Met. 0 0 4 11
Lymph Node Met. 29 0 310 65
Local Relapse 1 0 2 7
Lesion-based NPVand PPV 30/348 (8.6 %) 0/98 (0 %) 318/348 (91.4 % NPV) 98/98 (100 % PPV)
Lesion-based Specificity and Sensitivity 30/128 (23.4 %) 0/318 (0 %) 318/318 (100 % Specificity) 98/128 (76.6 % Sensitivity)
Patients: False-Negative False-Positive True-Negative True-Positive
1 0 0 0 1 (PCa)
2 0 0 1 (LN) 1 (LN)
3 0 0 2 (LN) 1 (LN)
4 0 0 9 (LN) 3 (ST)
5 0 0 15 (LN) 1+28 (ST/LN)
6 0 0 11 (LN) 1 (ST)
7 0 0 1+31 (ST/LN) 1+1 (ST/LN)
8 0 0 1 (ST) 2 (ST)
9 0 0 1 (LR) 0
10 0 0 11 (LN) 1 (PCa)
11 0 0 42 (LN) 1 (PCa)
12 0 0 12 (LN) 1 (PCa)
13 0 0 1 (PCa) 0
14 0 0 17 (LN) 1 (PCa)
15 0 0 14 (LN) 1 (PCa)
16 0 0 13 (LN) 1 (PCa)
17 0 0 0 1 (PCa)
18 0 0 37 (LN) 1 (LR)
19 0 0 0 1 (LR)
20 0 0 3 (LN) 1 (LR)
21 0 0 0 7 (LN)
22 0 0 0 1 (ST)
23 0 0 0 1 (PCa)
24 0 0 0 1 (PCa)
25 0 0 7 (LN) 1+2+2 (PCa/ST/LN)
26 1 (LN) 0 0 1 (PCa)
27 0 0 0 1 (PCa)
28 0 0 0 1 (LR)
29 0 0 24 (LN) 5+1 (LN/LR)
30 0 0 1 (LR) 0
31 1 (LR) 0 0 0
32 0 0 0 1 (LN)
33 0 0 0 1 (PCa)
34 26 (LN) 0 1+32 (ST/LN) 7 (LN)
35 0 0 1+16 (ST/LN) 1 (LN)
36 0 0 8 (LN) 1+1 (LR/LN)
37 2 (LN) 0 0 4 (LN)
38 0 0 1 (PCa) 0
39 0 0 0 1 (PCa)
40 0 0 0 1 (PCa)
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The lesion-based analysis of sensitivity, specificity, NPVand
PPV revealed values of 76.6, 100, 91.4 and 100 % (Table 3).
The patient-based analysis revealed a sensitivity of 88.1 %. As
described in the “Materials and methods” section, the latter
value needs to be interpreted with caution and a patient-based
calculation of specificity, NPVand PPV was not possible.
Follow-up information was available for 116 patients up to
the time this manuscript was submitted. Amongst these, 50
received local treatment: 27 were treated with external radia-
tion of PSMA-positive lesions (17 patients thereafter demon-
strated a decrease of PSA and in 10 patients PSA was not
available), 19 were operated and 4 were treated by high-
intensity focused ultrasound (all presented with a decrease of
PSA thereafter). Overall, 34 patients were treated by systemic
therapy with 131I- or 177Lu-labelled PSMA ligands (131I-
MIP1095 and the novel promising theranostic agent 177Lu-
DKFZ-PSMA-617 [21, 27]). All other patients (n=36) were
treated by ADT and/or chemotherapy.
Intraindividual changes in SUVmean/SUVmax values between
1 and 3 h p.i. weremeasured in the salivary glands of ten patients.
Between both scans, an excretion stimulus using vitamin C was
orally administered every 30 min as described in the “Materials
and methods” section. The SUV values as well as SUV changes
between 1 and 3 h p.i. (Fig. 5) were similar to our previous
evaluation inwhich no excretion stimulus was administered [19].
Discussion
Since the invention of the radiotracer Glu-NH-CO-NH-
Lys-(Ahx)-[68Ga(HBED-CC)] and its clinical introduction
for PET imaging at our institute in May 2011, this highly
promising method (68Ga-PSMA-ligand PET/CT) has rapidly
spread. The first clinical experiences led to the assumption
that 68Ga-PSMA-ligand PET/CT could be a significant step
forward in the diagnosis of recurrent PCa [18–20, 26]. This
imaging modality is based on the observation that almost all
adenocarcinomas of the prostate gland express PSMA to
which Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] is able
to bind with very high affinity [28, 29]. The aim of this evalu-
ation was to assess 319 patients who were referred to our
hospital for 68Ga-PSMA-ligand PET/CT from the first clinical
implementation of this method inMay 2011 until January 2014.
Overall, 82.8 % of the patients presented with at least one
lesion characteristic for PCa in 68Ga-PSMA-ligand PET/CT. This
rate is slightly lower compared to our previous reports [19, 20]. A
Fig. 5 Average SUVmean/
SUVmax values of ten patients
who received excretion stimulus
between the first 68Ga-PSMA-
ligand PET/CT (1 h p.i.) and the
second PET/CT (3 h p.i.). As
demonstrated, the excretion
stimulus did not reduce the high
physiological radiotracer uptake
of the salivary glands
Table 3 (continued)
All Lesions: False-Negative False-Positive True-Negative True-Positive
41 0 0 2 (LN) 5 (LN)
42 0 0 3 (LN) 1 (LR)
Patient-based Analysisa 5/42 (11.9 %) not existing not existing 37/42 (88.1 % Sensitivity)a
The false-negative LN metastases of patients 35 and 37 were located in the same region as the PET-positive LNs
PCa prostate cancer within the prostate gland, LN lymph node (metastasis), ST soft tissue (metastasis), LR local relapse of PCa
aAs described in the “Materials and methods” section, a patient-based analysis of specificity, NPVand PPV is not possible
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possible explanation is that our previous studies were con-
ducted in the initial phase of imaging with this novel method
and that after 68Ga-PSMA-ligand PET/CT became increas-
ingly better known, more challenging cases with negative
alternative imaging results and low PSA values were referred
to our hospital.
In the multivariate analysis a strong association was
detected between a pathological 68Ga-PSMA-ligand
PET/CT and the PSA level. This result was expected
as an increase in PSA levels usually indicates progres-
sive disease. However, as demonstrated by Fig. 3, a
continuous increase in PSA level does not automatically
correlate with an increase in tumor detection. In general
the question remains why not more patients show a
pathologic 68Ga-PSMA-ligand PET/CT although accord-
ing to literature almost all prostatic adenocarcinomas
express PSMA [28, 29]. Possible reasons could be the
individual tumor heterogeneity, a dedifferentiation of
PCa leading to a decoupling of tumor mass and PSA
level, absent or very low PSMA expression of some
tumors (e.g. neuroendocrine PCa), tumors adjacent to
the urinary bladder, small tumour size below the spatial
resolution of the PET scanner or the stage of technology
of the PET scanner. With regard to the latter aspect we
believe for example that new scanners with time of
flight (TOF) technology enable more sensitive tumour
detection.
In the most challenging cohort (patients with PSA
<0.2 ng/ml) GSC was significantly higher in the group with
pathological 68Ga-PSMA-ligand PET/CT compared to the
group without pathological 68Ga-PSMA-ligand PET/CT.
However, with regard to all patients analysed in this evalua-
tion, the multivariate analysis did not show a relevant associ-
ation between a positive 68Ga-PSMA-ligand PET/CT and
GSC 7, 8 or 9–10 compared to a low GSC of 5–6. This result
is contrary to our expectations: in the literature, a positive
correlation between higher GSC and PSMA expression
has been demonstrated in preclinical studies [30–32]. The
sole explanation we have at this stage is that the small
cohort of patients with GSC 5–6 causes substantial vari-
ability in the statistical analysis. We consider GSC as an
important variable in both imaging and therapy with
PSMA ligands. Further studies focusing on this topic are
eagerly awaited.
The multivariate analysis also did not demonstrate a rele-
vant association between a positive 68Ga-PSMA-ligand PET/
CT and the five defined PSA DTs. At this stage, we assume
that there is no significant correlation between proliferation
index and PSMA expression of the tumours.
Patients with an ADT at the time of 68Ga-PSMA-ligand
PET/CT more frequently showed a positive PET scan com-
pared to patients without such treatment. One explanation for
this result could be that patients with advanced disease are
more often referred to ADT. However, this theory needs to be
investigated in more detail as many cases exist in which ADT
is started at low PSA values. We believe that the time to start
ADT depends on many variables such as patients’ demands,
preferences/experience of physicians, PSA DT, etc. In addi-
tion, ADT usually leads to a reduction of PSA levels and can
also reduce the tumour size [33, 34]. Both have the potential to
negatively influence the detection rate in imaging modalities.
Another explanation for our findings could be that the PSMA
expression is apparently differentially regulated by androgens.
In previous preclinical studies, PSMA expression was down-
regulated by androgen therapy and upregulated by
antiandrogen therapy [35–37]. This counterintuitive behav-
iour is not yet fully understood and more studies are eagerly
awaited to investigate the influence of ADTon both diagnosis
and therapy with PSMA ligands.
A noticeable but nonsignificant positive association was
also detected between a positive 68Ga-PSMA-ligand PET/CT
and lower amounts of injected radioactivity. However, accord-
ing to our experience in routine clinical practice, tracer activ-
ities of more than 100–120 MBq lead to improved image
quality while especially amounts less than 60–70 MBq cause
the opposite. At this stage, our sole explanation for this unex-
pected finding is statistical variability. We do not believe that
higher radioactivity amounts lead to any adverse molecular
interaction as all injections contained 2 nmol PSMA ligand.
The analysis of SUV values within the manifestations of
PCa demonstrate that uptake of 68Ga-PSMA-HBED-CC is
high in primary tumours as well as in local relapses and all
types of metastases. This result confirms our previous evalu-
ation in which we could demonstrate that the total uptake of
PCa lesions as well as tumour contrast are significantly higher
compared to choline PET/CT [20]. However, as shown in the
aforementioned evaluation, it has to be considered that lymph
node metastases usually present with the highest contrast,
followed by bone metastases, local relapses and soft tissue
metastases.
We assume that virtually all patients referred to our hospital
had recurrent disease or persistent primary tumour and that
our cohort did not include true-negative cases. Therefore,
calculating patient-based specificity, NPV and PPV is not
possible as described in the “Materials and methods” section.
However, with regard to a lesion-based analysis, it is apparent
that 68Ga-PSMA-HBED-CC is able to detect PCa with good
sensitivity and excellent specificity (Table 3). Only 1 local
relapse in 1 patient and 29 lymph node metastases in 3 other
patients were false-negative. With regard to two of the latter
patients (patients 34 and 37 in Table 3), PET-positive lymph
nodes led to lymph node dissection of the pelvis where addi-
tional small lymph node metastases were found. These PET-
negative lymph nodes were located in the same region as the
PET-positive lymph nodes and had therefore no negative
influence on the therapy procedure. We assume that the
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mentioned metastases were not detected by 68Ga-PSMA-
ligand PET/CT due to a small size and low PSMA expression.
However, with the exception of the above-mentioned PET-neg-
ative metastases in four different patients, all other lesions (n=
416) were true-positive or true-negative. This result demon-
strates that 68Ga-PSMA-HBED-CC is highly specific for PCa.
However, theoretically an expression of PSMA within inflam-
matory lesions can exist, although it is considered to be rare [29].
Overall, the histology results need to be interpreted with
caution, e.g. cases with different numbers of lymph node
metastases usually cause a bias. In addition, there was no
standardized protocol to investigate PET-positive lesions. Cal-
culating patient-based values of specificity, NPV and PPV is
therefore not reasonable as mentioned before. The most im-
portant message of the histology results is that 68Ga-PSMA-
HBED-CC is highly specific for PCa. At this stage, we sug-
gest that accumulations of 68Ga-PSMA-HBED-CC in lesions
outside the prostate gland have to be regarded as PCa-specific
until proven otherwise. In addition, we suggest that specifica-
tion of a cut-off SUV for malignant or benign tissue is not
reasonable for lesions outside of the prostate gland. On the
other hand, for lesions within the prostate gland, calculation of
such cut-off SUVs can possibly help to distinguish different
GSC or tumour and inflammatory tissue. However, such cut-
offs cannot be provided by this evaluation as a sufficient
number of benign tissues need to be analysed. Stereotactic
biopsy studies are underway to provide more data.
Among the 116 patients who were available for follow-up,
50 (40 %) were treated locally after 68Ga-PSMA-ligand PET/
CTand therefore delayed systemic therapy due to the results of
the 68Ga-PSMA-ligand PET/CT. We believe that such patients
who can delay systemic therapy have a greater potential for
improved quality of life. Systemic therapies usually present
with significant side effects and the therapeutic effect is fre-
quently temporary. It also has to be considered that patients
who present with locally accessible tumours have theoretically
a better chance to be cured of their disease. However, long-
term studies are necessary to evaluate the impact of 68Ga-
PSMA-ligand PET/CTon the overall survival time and quality
of life of PCa patients.
In this evaluation we could also demonstrate that a sour
excretion stimulus does not reduce the high physiological
radiotracer uptake of the salivary glands. We therefore assume
that such a stimulus would not help to reduce radiation-related
side effects of therapy with radiolabelled PSMA ligands.
Our retrospective analysis shows typical limitations com-
pared to prospective studies: biased patient referrals and there-
by possibly biased treatments and follow-up as well. Howev-
er, we believe that our data reflect the daily clinical routine and
that every centre which conducts 68Ga-PSMA-ligand PET/CT
faces similar conditions. Our results and messages therefore
can help to better understand PSMA imaging until more data
are available in the future.
Conclusion
This evaluation investigated the diagnostic value of PET/CT
imaging with the new 68Ga-labelled PSMA ligand HBED-CC
(68Ga-DKFZ-PSMA-11) in the diagnosis of PCa. 68Ga-
PSMA-ligand PET/CT 1 h p.i. can detect PCa in a high
percentage of patients with suspected cancer (82.8 %). In
addition, the tracer is highly specific for PCa: histological
analysis demonstrated that accumulation of 68Ga-PSMA-
HBED-CC in lesions correlates with manifestations of PCa
in virtually all cases and false-positive lesions could not be
detected. Detection of PCa is improved at higher PSA levels.
Also, ADT had a significantly positive influence on tumour
detection rate, which, however, has to be interpreted with
caution. However, no association was found between a posi-
tive PET/CT and faster PSA DTs as well as GSC 7, 8 or 9–10
compared to a low GSC of 5–6. Amongst all patients who
were available for follow-up after 68Ga-PSMA-ligand PET/
CT, 40 % could be treated locally with resulting delayed
systemic therapy. We could also demonstrate that an excretion
stimulus using vitamin C does not lead to a reduction of the
physiologically high 68Ga-PSMA-HBED-CC uptake in sali-
vary glands. With regard to possible therapy of metastatic PCa
with radiolabelled PSMA ligands, we therefore assume that
such an excretion stimulus would not help to reduce radiation-
based off-target effects to the salivary glands.
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